Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Updates in
BRAF V600E
-Mutated mCRC
9
Mins
March 2024
The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer, and is associated with poor prognosis. This…
Read more
10
Mins
13th August 2021
Trial Outcomes and Sub-Analyses of Direct Oral Anticoagulants in the Treatment of Cancer-Related Venous Thromboembolism: Interviews with Key Opinion Leaders
EMJ conducted interviews with two key opinion leaders and specialists in the prevention and treatment of cancer-related venous…
10
Mins
29th June 2021
PARP Inhibitors in Advanced Ovarian Cancer: A Review of Long-term Efficacy and Survival Rates
This article discusses the results published in 2020 and early 2021 from key clinical trials of PARP inhibitors in patients with advanced ovarian cancer in terms of long-term efficacy and survival rates.
10
Mins
4th May 2021
Reimagining Treatment of HR+, HER2- Early Breast Cancer
Dr Prat explained that there are three main variables that should be considered when determining the risk of recurrence for…
11
Mins
23rd March 2021
Addressing the Unmet Need in Treatment of Nonmelanoma Skin Cancers: Interviews with Two Key Opinion Leaders
Nonmelanoma skin cancers (NMSC) are a diverse group of cutaneous malignancies and are the most common forms of human neoplasia worldwide…
3
Mins
19th February 2021
Final Results from the ClarIDHy Phase III Study of Ivosidenib Versus Placebo in Patients with Previously Treated Cholangiocarcinoma and an Isocitrate Dehydrogenase 1 (IDH1) Mutation
Cholangiocarcinoma (CCA) is a rare cancer for which there are limited effective therapies.1,2 Mutations in the isocitrate dehydrogenase 1 gene (IDH1)…
5
Mins
8th February 2021
Streptococcus suis and an Incidentally Diagnosed Metastatic Colon Cancer
Streptococcus suis is a zoonotic gram-positive bacterium that is usually acquired through direct contact with swine or pork…
10
Mins
12th January 2021
Expanding Possibilities in EGFR-Mutated Advanced NSCLC: Interviews with Four Key Opinion Leaders
Worldwide, there were approximately 2.10 million patients diagnosed with, and 1.77 million deaths caused by, lung cancer in 2018. Approximately…
6
Mins
16th December 2020
3rd Breast Cancer Virtual Masterclass Symposium: MONARCH 2, a Phase III Study of Abemaciclib or Placebo in Combination with Fulvestrant
More than 70% of patients diagnosed with metastatic breast cancer present with oestrogen-HR+ disease and are therefore candidates for endocrine…
Loading posts...
« Previous
1
…
7
8
9
10
11
…
26
Next »